Evidence-Based Life Extension Research
A comprehensive analysis of the top 30 life-extending drugs and validated supplement categories based on strongest human clinical evidence, correcting erroneous longevity reports and identifying proven efficacious compounds.
The National Institute on Aging's Interventions Testing Program (ITP) has rigorously tested compounds in genetically diverse mice across three independent laboratories. Rapamycin emerged as the most reliable lifespan extender, extending median lifespan by 23% in males and 26% in females when initiated at 600 days of age.
Combination therapies show remarkable synergistic effects. Rapamycin combined with acarbose extended median lifespan by 34% in males and 28% in females. The rapamycin-trametinib combination achieved even greater results, extending median lifespan by 35% in females and 27% in males.
Critical finding: Rapamycin is the only drug that has been shown to extend both median and maximum lifespan in mice across all tested strains, with effects observed whether administered at young or old age.
Top Life-Extending Drugs: Evidence-Based Rankings
Based on rigorous mouse studies from the National Institute on Aging's Interventions Testing Program (ITP), these compounds demonstrate the strongest evidence for lifespan extension.
Evidence-Based Supplement Categories
Three distinct supplement categories based on strongest human clinical evidence for general health, organ function, and disease prevention.
Taurine
Extended average lifespan by 12% in female mice and 10% in males.
Glycine
Improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, and inflammation in older adults.
Folic Acid
Reduced risk of stroke by 15% (RR = 0.85) in meta-analysis of RCTs.
Coenzyme Q10
Significantly reduces mortality (RR 0.64) and hospitalizations for heart failure (RR 0.50) in 2024 meta-analysis.
Magnesium
Modestly lowers systolic BP by 2-3 mmHg, particularly in individuals with suboptimal magnesium status.
Creatine
Improves whole-body lean mass by approximately 1.2 kg more than resistance training alone.
Organ-Specific Benefits
Multiple supplements show targeted organ benefits. Silymarin from milk thistle significantly reduced liver enzymes (AST, ALT), improved lipid profiles, and showed histological evidence of reduced hepatic steatosis in MASLD patients at doses of 420-600 mg daily.
Curcumin demonstrated measurable reduction of liver fat via imaging in MASLD patients, with effective doses ranging from 250 mg to 3000 mg daily. The phytosomal form showed better therapeutic effect.
Caution: While many nutraceuticals have been studied for NAFLD, none have sufficient evidence to recommend their routine use according to position papers on management.
Human Clinical Evidence: Meta-Analyses and RCTs
Large-scale human studies providing robust evidence for supplement efficacy and safety profiles.
VITAL Trial: Vitamin D3 & Omega-3
Large-scale RCT with 25,871 participants. Vitamin D3 (2000 IU/day) for 5.3 years showed no significant benefit for primary outcomes.
Secondary finding: n–3 fatty acids showed potential benefit for MI (HR 0.72), but this requires further validation.
Dietary Supplements Meta-Analysis
Systematic review of 49 trials (69 reports) involving 287,304 participants concluded insufficient evidence for most supplements.
Vitamin D Meta-Analysis
Meta-analysis of 80 RCTs found no significant reduction in all-cause mortality (OR 0.96, 95% CI: 0.92-1.00).
Warning: No significant benefit observed for cardiovascular mortality, stroke, or heart failure.
Dietary Fiber Meta-Analysis
Umbrella review of 31 meta-analyses found significantly reduced relative risk for cardiovascular disease (RR = 0.72-0.91).
Aging Mechanisms and Rapamycin's Role
Understanding the biological pathways underlying aging and how rapamycin targets these processes.
mTOR Pathway and Cellular Senescence
Rapamycin acts on the Ras/Insulin/TOR signalling network, extending mouse longevity by 15-20% when administered from six months of age onwards. It is described as a potent geroprotector.
The combination therapy of rapamycin and trametinib demonstrated synergistic effects, increasing mouse longevity by around 30%, which is greater than the sum of their individual effects.
The combination therapy improved health in old-age mice by decreasing age-related brain glucose uptake, reducing inflammation across multiple organs (brain, kidney, spleen, muscle), and lowering circulating pro-inflammatory cytokines.
Cancer protection: The combination therapy reduced the occurrence of liver tumours in both sexes and spleen tumours in male mice, suggesting a protective effect against certain age-related cancers.
Human Clinical Trials
The PEARL trial, a 48-week randomized, placebo-controlled study, found that low-dose, intermittent rapamycin (10 mg weekly) is safe in healthy adults aged 50–85.
Women: 6% increase in lean mass at 48 weeks
Self-reported pain, emotional well-being, and general health improved
No serious adverse events reported
Caution: In a phase 2b/phase 3 trial, 1 mg sirolimus daily resulted in concerning metabolic changes including decreased plasma albumin, increased triglycerides, and increased HbA1C.
Telomere Lengthening
SGLT2 inhibitors like henagliflozin (10 mg/day) demonstrated telomere lengthening in a 6-month clinical study, reversing a key marker of biological aging.
Senescence Inhibition
SGLT2 inhibitors inhibit cellular senescence in multiple tissues, reducing markers of senescence and decreasing pro-inflammatory SASP cytokines.
GLP-1 Agonists
Large patient datasets show no meaningful increase in overall cancer incidence with GLP-1 agonists. Early evidence suggests reduced risk for obesity-related cancers.
Evidence Quality Assessment Framework
Applying rigorous grading systems to evaluate the strength and certainty of evidence for longevity interventions.
USPSTF Evidence Grades
Grade A
High certainty of substantial net benefit. Recommend offering or providing service.
Grade B
High certainty of moderate net benefit or moderate certainty of moderate to substantial benefit. Recommend offering or providing service.
Grade C
Moderate certainty of small net benefit. Selectively offer based on professional judgment and patient preferences.
Grade D
Moderate or high certainty of no net benefit or harms outweigh benefits. Recommend against the service.
I Statement
Insufficient evidence to assess balance of benefits and harms. Current evidence is lacking, of poor quality, or conflicting.
GRADE Certainty Levels
High Certainty
High confidence that the true value is on one side of a threshold.
Moderate Certainty
Moderately confident in the estimate, but confidence constrained by study factors.
Low Certainty
Low confidence in the estimate due to limited studies, important flaws, or gaps.
Very Low Certainty
Very low confidence in the estimate. True effect is likely substantially different.
Conclusion: Evidence-Based Longevity Priorities
Top Priority: Rapamycin and Combination Therapies
Rapamycin stands as the most robustly validated life-extending compound, with consistent 23-26% lifespan extension in both male and female mice across multiple ITP studies. The combination of rapamycin and acarbose achieves the strongest recorded lifespan extension: +37% in males and +28% in females.
Human clinical trials show rapamycin is relatively safe at low doses, with intermittent 10 mg weekly doses improving lean mass and self-reported health metrics in healthy adults aged 50–85.
Strong Supporting Evidence: SGLT2 Inhibitors and GLP-1 Agonists
SGLT2 inhibitors represent a breakthrough in reversing biological aging markers, with 6-month interventions demonstrating measurable telomere elongation in patients with type 2 diabetes.
GLP-1 receptor agonists show strong human outcome evidence, with the SELECT trial recording fewer major cardiovascular events and deaths among over 17,000 participants, reducing major cardiovascular events by 20%.
Well-Established Supplements: Cardiovascular and Cognitive Benefits
Coenzyme Q10 supplementation significantly reduces mortality (RR 0.64) and hospitalizations for heart failure (RR 0.50) according to 2024 umbrella meta-analysis.
Multivitamin supplementation shows strong cognitive benefits, with meta-analysis of over 5,000 participants finding it slowed global cognitive aging by the equivalent of two years compared to placebo.
Folic acid supplementation reduced the risk of stroke by 15% (RR = 0.85) in meta-analysis of RCTs totaling 115,559 participants.
Critical Distinctions: What Doesn't Work
The NIA ITP has tested 54 compounds over 20 years, with 47 failing to extend lifespan. Substances that showed no effect include Resveratrol, Nicotinamide riboside (NR), Fisetin, Fish oil, Curcumin, Green tea extract, Alpha-ketoglutarate, and Metformin.
Curcumin has never been shown to extend lifespan in any mammal studied. In male F1 hybrid mice, it had no effect on lifespan when fed starting at 12 months of age.
Critical principle: If a drug does not extend lifespan in mammals like mice, there is no reason to believe it will work in humans. Surrogate trials measuring disease prevention are more feasible than direct lifespan trials in humans.
Quality Assessment Framework
A proposed evidence hierarchy for longevity research prioritizes Randomized Controlled Trials (RCTs) as gold standard for proving cause-and-effect relationships, followed by Cohort and Observational Studies, Animal Studies, and In-Vitro Studies.
The proposed grading system categorizes molecules into four tiers: Tier A (FDA-approved specifically for aging with multiple Phase 3 trials), Tier B (completed human RCTs on healthspan endpoints), Tier C (pilot/observational/small-study human data), and Tier D (animal or laboratory evidence only).